Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Metformin/rosuvastatin (Primary) ; Metformin; Rosuvastatin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Yuhan
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.